# TELA Bio, Inc. (TELA) · Edgar & Edgarette company card

> TELA Bio (TELA) grew revenue 15.8% in FY2025 to $80 million, operating margin -42.0% against a 1.2% median for surgical & medical instruments & apparatus, equity 7.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1561921 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/TELA) · [JSON](https://www.pops4.com/boards/company/TELA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $80M |
| Revenue growth, 1 year | 15.8% |
| Revenue growth per year | 28.5% |
| Operating margin | -42.0% (prior year -49.2%) |
| Net margin | -48.4% |
| Operating cash flow | −$28M |
| Capital spending | $448,000 |
| Free cash flow | −$29M |
| Cash | $51M |
| Long-term debt | $56M |
| Total assets | $81M |
| Total equity | $6M |
| Equity ÷ assets | 7.8% |
| Return on equity | -615.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -13.97 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -3.32 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed restructuring or exit costs in the last 12 months; operating cash flow was negative; operating loss: a margin of -42.0% in FY2025; revenue is hard to predict: its 80% range is ±32%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $80.3M (FY2025), total debt $55.7M. Experience: revenue up 15.8% on the year, up 28.5% a year over 4 years; operating margin -42.0%, up from -49.2%. Soundness: equity 7.8% of assets, return on equity -615.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $66.9M and $130.7M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $68.6M to $127.6M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -42.0% against a 1.2% median; growth 15.8% against 11.6%.

Range logged 2026-09-30, receipt 6819176d70f229bb, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-09-18 ([filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926108935/0001104659-26-108935-index.htm))
- Item 2.05 Restructuring or exit costs: 1, latest 2026-08-31 ([filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926103548/0001104659-26-103548-index.htm))
- Item 5.02 Director or officer change: 4, latest 2026-08-31 ([filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926103548/0001104659-26-103548-index.htm))

## Recent filings

- 8-K · filed 2026-10-08 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926114695/0001104659-26-114695-index.htm)
- 8-K · filed 2026-10-06 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926114042/0001104659-26-114042-index.htm)
- 8-K · filed 2026-10-05 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926113506/0001104659-26-113506-index.htm)
- 8-K · filed 2026-09-29 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926111920/0001104659-26-111920-index.htm)
- 8-K · filed 2026-09-18 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926108935/0001104659-26-108935-index.htm)
- DEF 14A · filed 2026-09-14 · [filing](https://www.sec.gov/Archives/edgar/data/1561921/000110465926107491/0001104659-26-107491-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001561921.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1561921

## Cite

POPS4, Edgar & Edgarette: TELA Bio, Inc. (TELA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/TELA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.